A side-chain-modified dual-acting GLP-1/GIP molecule is currently in development for diabetes14, and a side-chain-modified analogue of amylin is being investigated for the treatment of obesity (ClinicalTrials.gov ID NCT03600480). The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.